Momelotinib for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Feb 2025: Trial registered, NCT06847867
  2. 5 Jun 2025: Trial started, NCT06847867

The trials

NCT06847867: A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

State
Under way
Phase
Phase 2
People
80 planned
Started
5 Jun 2025
Primary completion
14 Jul 2027
Arms
Momelotinib dose level 1, Momelotinib dose level 2
Results
None posted
  1. 26 Feb 2025: Trial registered
  2. 5 Jun 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.